Opioids
USF Health studies suggest new opioid-receptor signaling step could guide development of safer painkillers
በAI የተዘገበ በ AI የተሰራ ምስል እውነት ተፈትሸ
Researchers at USF Health report evidence that an early step in mu opioid receptor signaling can run in reverse, and that certain experimental compounds can enhance morphine- and fentanyl-driven pain relief in lab tests without increasing respiratory suppression at very low doses. The findings, published Dec. 17 in Nature and Nature Communications, are framed as a blueprint for designing longer-lasting opioids with fewer risks, though the newly tested molecules are not considered clinical drug candidates.
A comprehensive analysis of opioid medications for short-term pain has concluded that these drugs typically provide only modest and brief relief. The review, covering dozens of conditions, found that opioids often perform no better than placebos in many cases. Researchers from the University of Sydney led the effort and highlighted risks of side effects and dependence.
በAI የተዘገበ
A comprehensive review of clinical trials indicates that tramadol, a widely prescribed opioid for chronic pain, offers only slight relief that may not be noticeable to many patients. However, it significantly increases the risk of serious side effects, particularly heart-related issues. Researchers recommend minimizing its use due to these concerns.